Claudin18.2 targeted CAR-T (Zhaotai)

Claudin18.2靶向CAR-T（昭泰医疗）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameClaudin18.2 targeted CAR-T (Zhaotai)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > PMBC-derived
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsLung NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangdong Zhaotai Invivo Biomedicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Zhaotai Invivo Biomedicine Co LtdHunan Zhaotai Yongren Medical Innovation Co Ltd
Inactive CompaniesN/A
Active IndicationsLung Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A